Sponsored Links
| Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions In Serum Triglycerides In Preclinical Testing |
 |
 |
 |
| Medical News - Cholesterol | |||
|
Spherix Incorporated (NASDAQ: SPEXD) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and... Read more: Cholesterol News From Medical News Today
|